However, to date, only imatinib has been approved as a first-line treatment for patients with myeloid disease, with eosinophilia expressing FIP1L1-PDGFRα or carrying other PDGFRα or PDGFRβ fusions [107,117] (Table 2). This evidence concerns the gene FIP1L1 and Increased total eosinophil count.